Back to News
Market Impact: 0.35

New Strong Sell Stocks for September 11th

REFIELVTAP
Analyst InsightsAnalyst EstimatesCorporate EarningsCompany FundamentalsInvestor Sentiment & Positioning
New Strong Sell Stocks for September 11th

Zacks has added Chicago Atlantic Real Estate Finance (REFI), Elevance Health (ELV), and Molson Coors Beverage Company (TAP) to its Rank #5 (Strong Sell) list on September 11th. This designation follows significant downward revisions in their current year earnings estimates over the past 60 days, with REFI seeing a 1.7% revision, ELV a substantial 13.2% revision, and TAP a 6.4% revision, indicating a deteriorating financial outlook for these companies.

Analysis

Three companies across distinct sectors—Chicago Atlantic Real Estate Finance (REFI), Elevance Health (ELV), and Molson Coors Beverage Company (TAP)—have been downgraded to a 'Strong Sell' status by Zacks. This negative rating action is directly attributable to downward revisions in their respective Zacks Consensus Estimates for current-year earnings over the preceding 60 days. The magnitude of these revisions varies, with Elevance Health experiencing a substantial 13.2% reduction, followed by Molson Coors at 6.4%, and Chicago Atlantic with a more modest 1.7% cut. The downgrade of ELV is particularly notable due to the double-digit percentage decline in its earnings forecast, suggesting a significant deterioration in its perceived profitability. These revisions collectively signal a negative shift in analyst sentiment regarding the fundamental short-term outlook for these specific firms.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

mixed

Sentiment Score

0.10

Ticker Sentiment

ELV-0.80
REFI-0.75
TAP-0.75

Key Decisions for Investors

  • Investors holding long positions in REFI, ELV, and TAP should reassess their investment thesis, as the 'Strong Sell' ratings are predicated on weakening earnings outlooks.
  • The 13.2% downward earnings revision for Elevance Health (ELV) represents a significant red flag, warranting a deeper investigation into potential company-specific issues or sector-wide headwinds.
  • These analyst downgrades may act as a negative catalyst, presenting a potential rationale for portfolio managers to consider underweighting these stocks or exploring them as candidates for short positions.